U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
Gilead Sciences said that its third-quarter profit rose 17 percent on higher sales of its best-...
FDA advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from...
The Food and Drug Administration has issued a positive review for a highly anticipated hepatitis...
The Food and Drug Administration holds a public meeting this week to review two experimental medications from Johnson & Johnson and Gilead Sciences. The new drugs, if approved, could offer a quicker, more effective approach to eliminating hepatitis C, a blood-borne disease blamed for 15,000 deaths in the U.S. this year.
Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences has announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.
The FDA has approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs.
Shares of Gilead Sciences Inc. rose to all-time highs Friday after the company reported its first-quarter results and new trial data for two of its experimental hepatitis C drugs. THE SPARK: Gilead posted its quarterly results after the market closed Thursday. The company said its net income...
Gilead said sales of its two biggest-selling drugs, the HIV medicines Atripla and Truvada, both fell. But its total revenue increased because of stronger sales of other products, including other HIV drugs, its heart drug Letairis, angina treatment Ranexa, and growing sales of Stribild, a four-in-one HIV pill that was approved in August.
Gilead Sciences today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection.
Idenix Pharmaceuticals Inc. shares sank Monday after the U.S. Patent and Trademark Office determined a competitor was the first to request a patent for a hepatitis therapy. The biopharmaceutical company said an appeals board decided that Idenix's patent application for compounds used to treat hepatitis C was filed after Gilead Pharmasset LLC's application.
Shares of Gilead Sciences Inc. moved higher Tuesday after the company reported more clinical trial data for an experimental HIV pill.Gilead had previously said the new pill, called TAF, worked about as well as the company's Stribild tablet in a mid-stage clinical trial, but had lower rates of side effects related to kidney problems and bone loss.
Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch SurveyMarch 4, 2013 7:59 am | News | Comments
More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.
Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread® (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.
Gilead Issues a Voluntary Recall of One Lot of Vistide® (Cidofovir Injection) Due to Presence of Particulate MatterFebruary 19, 2013 8:10 am | News | Comments
Gilead Sciences, Inc. has announced it is voluntarily recalling lot B120217A of Vistide ® (cidofovir injection) to the user level due to the presence of particulate matter found in some vials of this lot. Effects from intravenous injection of product with particulate matter can vary depending on the amount of particulate matter injected into the patient.
HIV drug maker Gilead Sciences Inc. said Monday that its fourth-quarter profit grew nearly 15 percent on higher sales of antiviral drugs, edging past analyst estimates. For the quarter ended Dec. 31 Gilead Sciences earned $762.5 million, or 47 cents per share, up from $665.1 million, or 43 cents per share, in the last quarter of 2011.
Gilead Sciences, Inc. and YM BioSciences Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.
FOSTER CITY, Calif. (AP) — HIV drug maker Gilead Sciences Inc. said Monday that its board approved a two-for-one stock split that will take effect in January.
European Commission Approves Viread® for HIV-1 Infection in Children and Adolescents and for Chronic Hepatitis B in AdolescentsNovember 28, 2012 3:05 am | News | Comments
Gilead Sciences, Inc. has announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread® (tenofovir disoproxil fumarate).
Gilead’s Once-Daily Single Tablet HIV Regimen Maintains High Viral Suppression Through Two Years of TherapyNovember 15, 2012 3:17 am | News | Comments
Gilead Sciences today announced two-year (96-week) results from two pivotal Phase 3 studies (Studies 102 and 103) evaluating the company’s newest single tablet HIV regimen, Stribild TM (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), among treatment-naïve patients with HIV-1 infection.
NEW YORK (AP) — Shares of Gilead Sciences Inc. rose Monday after a JPMorgan analyst increased his price target on the stock and forecast higher sales of Stribild, Gilead's newest HIV pill.
The agency approved Gilead Sciences' Stribild as a once-a-day treatment to control HIV in adults who have not previously been treated for infection.
ATLANTA (AP) — U.S. health officials said Thursday that doctors should consider giving an AIDS prevention pill to women and heterosexual men who are at high risk for getting the virus
Gilead Sciences entered into agreements with Mylan, Ranbaxy, and Strides Arcolab to promote access to generic versions of emtricitabine-based antiretroviral therapies for HIV in developing countries.
In a speech at the opening session of the XIX International AIDS Conference (AIDS 2012), Health and Human Services (HHS) Secretary Kathleen Sebelius announced a series of innovative public-private partnerships in the fight against the HIV/AIDS epidemic.
A coalition of AIDS advocates, spearheaded by AIDS Healthcare Foundation, have sent a letter today to the CEO of HIV/AIDS drug maker Gilead Sciences, Inc., John C. Martin, urging the company not to "decimate ADAP [AIDS Drug Assistance Programs]" by pricing its latest HIV/AIDS drug combination-known as the "Quad"-higher than Gilead's Atripla, the most prescribed HIV/AIDS medication.
While Truvada's supporters say the drug is an important new option to stop the spread of AIDS, critics worry that the drug could give users a false sense of security and encourage risky behavior.
CHICAGO (AP) — Condoms and other safe-sex practices have accomplished only so much. Now the 30-year battle against AIDS is on the verge of a radical new phase, with the government expected to endorse a once-a-day pill to prevent infection with the virus.
In a series of votes, an FDA advisory panel recommended approval of the daily pill Truvada for healthy people who are at high risk of contracting HIV, including gay and bisexual men and heterosexual couples with one HIV-positive partner.
- Page 1